New antileukemic agents

Pediatric Hematology and Oncology

Volumn 20, Issue 3, 2003, Pages 173-185

  Mantadakis, Elpis ^a   Kalmanti, Maria ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

DNA hypomethylators; Farnesyl transferase; Inhibitors; Kinase inhibitors; Monoclonal antibodies; Nucleoside analogs

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 5 AZA 2' DEOXYCYTIDINE; ALETUZUMAB; ANGIOGENESIS INHIBITOR; ANTILEUKEMIC AGENT; CYTARABINE; FLT3 LIGAND; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GUANINE ARABINOSIDE; IMATINIB; INTERFERON; MIDOSTAURIN; MONOCLONAL ANTIBODY; NELARABINE; NUCLEOSIDE DERIVATIVE; PK 1166; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; SEMAXANIB; SEMIXANIB; TIPIFARNIB; TROXACITABINE; UNCLASSIFIED DRUG; VATALANIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHILDHOOD LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DESQUAMATION; DNA METHYLATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SOLUBILITY; GENE MUTATION; HAND FOOT SYNDROME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERBILIRUBINEMIA; LIVER DYSFUNCTION; LIVER TOXICITY; MALIGNANT TRANSFORMATION; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; ONCOGENE RAS; PANCYTOPENIA; PROGNOSIS; PRURITUS; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0037395237     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010390158928     Document Type: Review

References (70)

1. Giles FJ. Novel agents for the therapy of acute leukemia. Curr Opin Oncol. 2002;14:3-9.
2. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998;339:605-615.
3. Traxler P, Bold G, Buchdunger E, et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev. 2001;21:499-512.
4. Savage DG, Antman KH. Imatinib mesylate: a new oral targeted therapy. N Engl J Med. 2002;346:683-693.
5. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000;105:3-7.
6. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
7. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the bcr-abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
8. Druker B. Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia. Semin Hematol. 2001;38(3 Suppl 8):9-14.
9. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myelogenous leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937.
10. Talpaz M, Silver RT, Druker B, et al. Gleevec[™]: an active drug in patients with Ph+ chronic myeloid leukemia in accelerated phase: updated results of a phase II study. Proc Am Soc Hematol. 2001; abstract 3509.
11. Sawyers CL, Hochhaus A, Feldman E, et al. Gleevec/Glivec (imatinib mesylate, STI-571) in patients with chronic myeloid leukemia in myeloid blast crisis: updated results of a phase II study. Proc Am Soc Hematol. 2001; abstract 3510.
12. Scappini B, Onida F, Kantarjian HM, et al. In vitro effects of STI571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer. 2002;94:2653-2662.
13. Hoover RR, Mahon FX, Melo JV, Daley GQ. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood. 2002;100:1068-1071.
14. O'Brien S, Talpaz M, Cortes J, et al. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer. 2002;94:2024-2032.
15. le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. 2000;95:1758-1766.
16. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cells. Blood. 2000;95:3498-3505.
17. Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanism of resistance. Blood. 2000;96:1070-1079.
18. Gambacorti-Passerini C, Barni R, le Coutre P, et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(1) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst. 2000;92:1641-1650.
19. Barthe C, Gharbi MJ, Lagarde V, et al. Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukemia with increasing resistance to STI571. Br J Haematol. 2002;119:109-111.
20. Roumiantsev S, Shah NP, Gorre ME, et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA. 2002;99:10700-10705.
21. Hofmann WK, Jones LC, Lemp NA, et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood. 2002;99:1860-1862.
22. Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid-leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002;99:3472-3475.
23. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood. 2002;100:1014-1018.
24. Donato NJ, Ji Wu JY, Alitar M, et al. Multiple resistance mechanisms identified through studies of cell lines derived from chronic myelogenous leukemia patients progressing on IMATINIB/STI571 therapy. Proc Am Soc Hematol. 2001; abstract 3206.
25. Champagne MA, Hershon L, Rosamilia M, et al. STI571 in the treatment of pediatric Philadelphia (Ph+) chromosome-positive leukemia: a Children's Oncology Group phase 1 study (P-9973). Proc Am Soc Clin Oncol. 2001; abstract 1466.
26. Stirewalt DL, Kopecky KJ, Meshinchi S, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 2001;97:3589-3595.
27. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752-1759.
28. Rombouks WJ, Blokland I, Lowenberg B, et al. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia. 2000;14:675-683.
29. Kiyoi H, Towatari M, Yokota S, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia. 1998;12:1333-1337.
30. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97:2434-2439.
31. Levis M, Tse KF, Smith BD, et al. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood. 2001;98:885-887.
32. Levis M, Abllebach J, Tse KF, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 2002;99:3885-3891.
33. Weisberg E, Boulton C, Louise K, et al. Inhibition of mutant FLT3 receptors in leukemia cells by a small molecule tyrosine kinase inhibitor. Proc Am Soc Clin Oncol. 2002; abstract 16.
34. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase I clinical laboratory correlative trial. Blood. 2001;97:3361-3369.
35. Kurzrock R, Cortes J, Ryback ME, et al. Phase II study of R115777, a farnesyltransferase inhibitor, in myelodysplastic syndrome. Proc Am Soc Hematol. 2001; abstract 3520.
36. Mansour TS, Jin H, Wang W, et al. Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2′-deoxy-3′-oxa-4′-thiocytidine and their 5-fluoro analogues in vitro. J Med Chem. 1995;38:1-4.
37. Grove KL, Guo X, Liu SH, et al. Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration. Cancer Res. 1995;55:3008-3011.
38. Grove KL, Cheng YC. Uptake and metabolism of the new anticancer compound beta-L-(-)-dioxolanecytidine in human prostate carcinoma DU-145 cells. Cancer Res. 1996;56:4187-4191.
39. Kadhim SA, Bowlin TL, Waud WR, et al. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models. Cancer Res. 1997;57:4803-4810.
40. Siu LL, Attardo G, Izbicka E, et al. Activity of (-)-2′-deoxy-3′-oxacytidine (BCH-4556) against human tumor colony-forming units. Ann Oncol. 1998;9:885-891.
41. Giles FJ, Cortes JE, Baker SD, et al. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol. 2001;19:762-771.
42. Lambe CU, Averett DR, Paff MT, et al. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res. 1995;55:3352-3356.
43. Ullman B, Martin DW. Specific cytotoxicity of arabinosyl-guanine toward cultured T-lymphoblasts. J Clin Invest. 1984;74:951-955.
44. Verhof V, Fridland A. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts. Cancer Res. 1985;45:3646-3650.
45. Kisor DF, Plunkett W, Kurtzberg J, et al. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol. 2000;18:995-1003.
46. Gandhi V, Plunkett W, Weller S, et al. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J Clin Oncol. 2001;19:2142-2152.
47. Herman JG, Jen J, Merlo A, et al. Hypermethylation-associated inactivation indicates a suppressor role for p15INK4B1. Cancer Res. 1996;56:722-727.
48. Jones PA, Taylor SM. Cellular differentiation, cytidine analogues and DNA methylation. Cell. 1980;20:85-93.
49. Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000;18:956-962.
50. Quesnel B, Fenaux P. P15INK4b gene methylation and myelodysplastic syndromes. Leuk Lymphoma. 1999;35:437-443.
51. Uchida T, Kinoshita T, Hotta T, et al. High-risk myelodysplastic syndromes and hypermethylation of the p15Ink4B gene. Leuk Lymphoma. 1998;32:9-18.
52. Ribatti D, Vacca A, De Falco G, et al. Angiogenesis, angiogenic factor expression and hematological malignancies. Anticancer Res. 2001;21:4333-4339.
53. Moehler TM, Neben K, Ho AD, et al. Angiogenesis in hematologic malignancies. Ann Hematol. 2001;80:695-705.
54. Keyhani A, Jendiroba DB, Freireich EJ. Angiogenesis and leukemia. Leuk Res. 2001;25:639-645.
55. Aguayo A, O'Brien S, Keating M, et al. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood. 2000;96:768-770.
56. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240-2245.
57. Smolich BD, Yuen HA, West KA, et al. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood. 2001;97:1413-1421.
58. Mendel DB, Schreck RE, West DC, et al. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res. 2000;6:4848-4858.
59. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999;59:99-106.
60. Mesters RM, Padro T, Bieker R, et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood. 2001;98:241-243.
61. Fiedler W, Tinnefeld H, Mende T, et al. A phase II study with SU5416 in patients with C-Kit positive AML. Proc Am Soc Clin Oncol. 2001; abstract 1148.
62. Flynn JM, Byrd JC. Campath-1H monoclonal antibody therapy. Curr Opin Oncol. 2000;12:574-581.
63. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol. 1997;15:1567-1574.
64. Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood. 2002;99:2245-2247.
65. Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002;20:205-213.
66. Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001;98:1721-1726.
67. Mylotarg [package insert]. Philadelphia, PA: Wyeth-Ayerst; May 2000.
68. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93:3678-3684.
69. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490-1496.
70. Sievers EL, Larson RA, Stadtmauer EA, et al., for the Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244-3254.